Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature

Alanna Maguire, Xianfeng Chen, Lee Wisner, Smriti Malasi, Colleen Ramsower, Samantha Kendrick, Michael Barrett, Betty Glinsmann-Gibson, Michael McGrath, Lisa Rimsza

Research output: Contribution to journalArticle

Abstract

Diffuse large B-cell lymphoma (DLBCL) is up to 17-fold more likely to occur, follows a more aggressive clinical course and frequently presents at advanced stages in HIV infected (+) individuals compared to HIV negative (−) individuals. However, the molecular pathology underpinning the clinical features of DLBCL in HIV(+) patients relative to the general population is poorly understood. We performed a retrospective study examining the transcriptional, genomic and protein expression differences between HIV(+) and HIV(−) germinal center B-cell (GCB) DLBCL cases using digital gene expression analysis, array comparative genomic hybridization (CGH) and immunohistochemistry (IHC). Genes associated with cell cycle progression (CCNA2, CCNB1, CDC25A, E2F1), DNA replication (MCM2, MCM4, MCM7) and DNA damage repair, including eight Fanconi anemia genes (FANCA, FANCD1/BRCA2, FANCE, FANCG, FANCR/RAD51, FANCS/BRCA1, FANCT/UBE2T, FANCV/MAD2L2), were significantly increased in HIV(+) GCB-DLBCL tumors compared to HIV(−) tumors. In contrast, genes associated with cell cycle inhibition (CDKN1A, CDKN1B) as well as apoptosis regulating BCL2 family members (BCL2, BAX, BIM, BMF, PUMA) were significantly decreased in the HIV(+) cohort. BCL2 IHC confirmed this expression. Array CGH data revealed that HIV(+) GCB-DLBCL tumors have fewer copy number variations than their HIV(−) counterparts, indicating enhanced genomic stability. Together, the results show that HIV(+) GCB-DLBCL is a distinct molecular malignancy from HIV(−) GCB-DLBCL; with an increased proliferative capacity, confirmed by Ki67 IHC staining, and enhanced genomic stability, the latter of which is likely related to the enhanced expression of DNA repair genes.

Original languageEnglish (US)
JournalInternational Journal of Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Genomic Instability
DNA Repair
HIV
Germinal Center
B-Lymphocytes
Comparative Genomic Hybridization
Immunohistochemistry
Genes
Neoplasms
Cell Cycle
Fanconi Anemia
Molecular Pathology
DNA Replication
DNA Damage
Retrospective Studies

Keywords

  • DNA repair
  • Fanconi anemia
  • GCB DLBCL
  • HIV

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature. / Maguire, Alanna; Chen, Xianfeng; Wisner, Lee; Malasi, Smriti; Ramsower, Colleen; Kendrick, Samantha; Barrett, Michael; Glinsmann-Gibson, Betty; McGrath, Michael; Rimsza, Lisa.

In: International Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Maguire, Alanna ; Chen, Xianfeng ; Wisner, Lee ; Malasi, Smriti ; Ramsower, Colleen ; Kendrick, Samantha ; Barrett, Michael ; Glinsmann-Gibson, Betty ; McGrath, Michael ; Rimsza, Lisa. / Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature. In: International Journal of Cancer. 2019.
@article{288bae43fd5d4d538902144bd82e5054,
title = "Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is up to 17-fold more likely to occur, follows a more aggressive clinical course and frequently presents at advanced stages in HIV infected (+) individuals compared to HIV negative (−) individuals. However, the molecular pathology underpinning the clinical features of DLBCL in HIV(+) patients relative to the general population is poorly understood. We performed a retrospective study examining the transcriptional, genomic and protein expression differences between HIV(+) and HIV(−) germinal center B-cell (GCB) DLBCL cases using digital gene expression analysis, array comparative genomic hybridization (CGH) and immunohistochemistry (IHC). Genes associated with cell cycle progression (CCNA2, CCNB1, CDC25A, E2F1), DNA replication (MCM2, MCM4, MCM7) and DNA damage repair, including eight Fanconi anemia genes (FANCA, FANCD1/BRCA2, FANCE, FANCG, FANCR/RAD51, FANCS/BRCA1, FANCT/UBE2T, FANCV/MAD2L2), were significantly increased in HIV(+) GCB-DLBCL tumors compared to HIV(−) tumors. In contrast, genes associated with cell cycle inhibition (CDKN1A, CDKN1B) as well as apoptosis regulating BCL2 family members (BCL2, BAX, BIM, BMF, PUMA) were significantly decreased in the HIV(+) cohort. BCL2 IHC confirmed this expression. Array CGH data revealed that HIV(+) GCB-DLBCL tumors have fewer copy number variations than their HIV(−) counterparts, indicating enhanced genomic stability. Together, the results show that HIV(+) GCB-DLBCL is a distinct molecular malignancy from HIV(−) GCB-DLBCL; with an increased proliferative capacity, confirmed by Ki67 IHC staining, and enhanced genomic stability, the latter of which is likely related to the enhanced expression of DNA repair genes.",
keywords = "DNA repair, Fanconi anemia, GCB DLBCL, HIV",
author = "Alanna Maguire and Xianfeng Chen and Lee Wisner and Smriti Malasi and Colleen Ramsower and Samantha Kendrick and Michael Barrett and Betty Glinsmann-Gibson and Michael McGrath and Lisa Rimsza",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ijc.32381",
language = "English (US)",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature

AU - Maguire, Alanna

AU - Chen, Xianfeng

AU - Wisner, Lee

AU - Malasi, Smriti

AU - Ramsower, Colleen

AU - Kendrick, Samantha

AU - Barrett, Michael

AU - Glinsmann-Gibson, Betty

AU - McGrath, Michael

AU - Rimsza, Lisa

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Diffuse large B-cell lymphoma (DLBCL) is up to 17-fold more likely to occur, follows a more aggressive clinical course and frequently presents at advanced stages in HIV infected (+) individuals compared to HIV negative (−) individuals. However, the molecular pathology underpinning the clinical features of DLBCL in HIV(+) patients relative to the general population is poorly understood. We performed a retrospective study examining the transcriptional, genomic and protein expression differences between HIV(+) and HIV(−) germinal center B-cell (GCB) DLBCL cases using digital gene expression analysis, array comparative genomic hybridization (CGH) and immunohistochemistry (IHC). Genes associated with cell cycle progression (CCNA2, CCNB1, CDC25A, E2F1), DNA replication (MCM2, MCM4, MCM7) and DNA damage repair, including eight Fanconi anemia genes (FANCA, FANCD1/BRCA2, FANCE, FANCG, FANCR/RAD51, FANCS/BRCA1, FANCT/UBE2T, FANCV/MAD2L2), were significantly increased in HIV(+) GCB-DLBCL tumors compared to HIV(−) tumors. In contrast, genes associated with cell cycle inhibition (CDKN1A, CDKN1B) as well as apoptosis regulating BCL2 family members (BCL2, BAX, BIM, BMF, PUMA) were significantly decreased in the HIV(+) cohort. BCL2 IHC confirmed this expression. Array CGH data revealed that HIV(+) GCB-DLBCL tumors have fewer copy number variations than their HIV(−) counterparts, indicating enhanced genomic stability. Together, the results show that HIV(+) GCB-DLBCL is a distinct molecular malignancy from HIV(−) GCB-DLBCL; with an increased proliferative capacity, confirmed by Ki67 IHC staining, and enhanced genomic stability, the latter of which is likely related to the enhanced expression of DNA repair genes.

AB - Diffuse large B-cell lymphoma (DLBCL) is up to 17-fold more likely to occur, follows a more aggressive clinical course and frequently presents at advanced stages in HIV infected (+) individuals compared to HIV negative (−) individuals. However, the molecular pathology underpinning the clinical features of DLBCL in HIV(+) patients relative to the general population is poorly understood. We performed a retrospective study examining the transcriptional, genomic and protein expression differences between HIV(+) and HIV(−) germinal center B-cell (GCB) DLBCL cases using digital gene expression analysis, array comparative genomic hybridization (CGH) and immunohistochemistry (IHC). Genes associated with cell cycle progression (CCNA2, CCNB1, CDC25A, E2F1), DNA replication (MCM2, MCM4, MCM7) and DNA damage repair, including eight Fanconi anemia genes (FANCA, FANCD1/BRCA2, FANCE, FANCG, FANCR/RAD51, FANCS/BRCA1, FANCT/UBE2T, FANCV/MAD2L2), were significantly increased in HIV(+) GCB-DLBCL tumors compared to HIV(−) tumors. In contrast, genes associated with cell cycle inhibition (CDKN1A, CDKN1B) as well as apoptosis regulating BCL2 family members (BCL2, BAX, BIM, BMF, PUMA) were significantly decreased in the HIV(+) cohort. BCL2 IHC confirmed this expression. Array CGH data revealed that HIV(+) GCB-DLBCL tumors have fewer copy number variations than their HIV(−) counterparts, indicating enhanced genomic stability. Together, the results show that HIV(+) GCB-DLBCL is a distinct molecular malignancy from HIV(−) GCB-DLBCL; with an increased proliferative capacity, confirmed by Ki67 IHC staining, and enhanced genomic stability, the latter of which is likely related to the enhanced expression of DNA repair genes.

KW - DNA repair

KW - Fanconi anemia

KW - GCB DLBCL

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=85066981298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066981298&partnerID=8YFLogxK

U2 - 10.1002/ijc.32381

DO - 10.1002/ijc.32381

M3 - Article

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -